Therapeutic Drug Monitoring of Factor VIII Prophylaxis Using Its Plasma Coagulant Activity and Global Hemostasis Biomarkers: A Pharmacokinetic/Pharmacodynamic Pilot Study
Background: The current clinical practice of factor VIII (FVIII) prophylaxis revolves around converting patients with severe hemophilia A, hereafter simply referred to as hemophilia, phenotype (defined as plasma factor VIII coagulant activity [FVIII:C] <1 IU dL-1) to moderate hemophilia phenotype...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2012
|
| Subjects: | |
| Online Access: | http://scholarscompass.vcu.edu/etd/2756 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=3755&context=etd |